Dihydroergotamine Results in Pain Relief Within 2 Hours for Acute Migraine

  • Dihydroergotamine
  • Headache
  • Migraine
  • Pain

In the pivotal phase 3 open-label STOP 301 study (NCT03557333), participants with migraine treated with dihydroergotamine mesylate (DHE) (INP104; Impel Neuropharma, Seattle, CA) administered to the upper nasal cavity experienced pain relief within 2 hours with quick uptake. The delivery device utilizes propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE deep into the vascular rich upper nasal space.

After a 28-day screening period, during which baseline frequency of migraine was measured, participants were able to self-administer up to 3 doses of DHE nasally per week (1.45 mg) to treat their migraine attacks. Among the participants, they reported 4,515 migraines total in the study. Within 2 hours of receiving the first dose of DHE, 38% of participants experienced freedom from migraine pain, 52% had freedom from most bothersome migraine symptom (MBS), and 66.3% experienced pain relief. Of the participants, 84% stated the device administering DHE was easy to use and they preferred it over current treatment.

The phase 3 STOP 301 study enrolled 360 participants who had a documented diagnosis of migraine with or without aura, with at least 2 attacks per month for the previous 6 months. The full safety set was comprised of the 354 participants who received at least 1 dose of DHE..  The primary safety set included the 185 participants who took an average of 2 or more DHE treatments per 28-day period during the 24-week treatment period. Of those enrolled, 74% (n=262) of participants completed the 24-week treatment period. 

The most common treatment-emergent adverse events (TEAEs) were nasal congestion (15%), nausea (6.8%), nasal discomfort, and unpleasant taste (5.1% each) with all other TEAEs being reported by less than 3% of participants. No treatment related serious adverse events, cardiac TEAEs or deaths were observed in the study.

Lasmiditan Treatment Provides Pain Freedom At 2 Hours in at Least 2 of 3 Migraine Attacks in New Phase 3 Study

Previous News Article

Erenumab Reductions in Monthly Migraine Days Sustained for up to 2 Years In Episodic Migraine

Next News Article
This Month's Issue
Physical and Cognitive Activity for Dementia

Ajay Sood, MD, PhD, and David Bennett, MD

Naturalistic Driving Measures

Ganesh M. Babulal, PhD, OTD, and Catherine M. Roe, PhD

Dementia Innovations

Nupur Ghoshal, MD, PhD